Used primarily as a key intermediate in the synthesis of immunomodulatory drugs, particularly in the production of lenalidomide and related compounds. It plays a critical role in targeted protein degradation therapies, especially in oncology. The compound functions as a precursor to cereblon E3 ligase modulators, which are employed in the treatment of multiple myeloma, myelodysplastic syndromes, and other hematological cancers. Its structure enables selective binding to cereblon, leading to the degradation of disease-causing proteins. Widely utilized in pharmaceutical research and development for designing novel proteolysis-targeting chimeras (PROTACs) and other degradation-based therapeutics.